A Single Ascending Dose (SAD) Study of LY3009385 in Healthy Volunteers.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs LY 3009385 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 13 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.